FDA to review its pediatric exclusivity decision for Amgen's Sensipar

A federal judge ordered FDA to address whether its decision to grant pediatric exclusivity to Ortho Tri-Cyclen norgestimate/ethinyl estradiol from the Janssen Pharmaceuticals Inc. unit

Read the full 251 word article

User Sign In